More than a million people start a GLP-1 every week

More than a million people begin treatment with a GLP-1 receptor agonist every week, a family of medicines built for diabetes that turned out to reduce body weight. In Argentina 73% of adults carry excess weight and 39% live with obesity, and one projection puts more than 26 million people at an elevated body mass index by 2030.

Obesity was read for decades as a problem of will, a social verdict wearing the clothes of a diagnosis. What changed is the biology. Gut hormones called incretins regulate appetite and metabolism, tirzepatide acts on two of those signals at once, GLP-1 and GIP, and people on these drugs describe something past eating less: the food noise goes quiet, the constant thinking about the next meal.

Price decides who ever finds out. Treatment with tirzepatide runs between 500,000 and 800,000 pesos a month depending on dose and coverage, and a patient support program discounts up to 30% of that. The economic gap shows up as plainly unequal access.

That does not mean these medicines are bending national curves. More than 16 million people are estimated to have been treated worldwide, and researchers tracking obesity say the effect is still hard to measure; the next round of statistics is where a population signal would first appear.

Read the full story at La Nación ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.